149 related articles for article (PubMed ID: 30921254)
41. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Armstrong D; Paré P; Pericak D; Pyzyk M;
Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
[TBL] [Abstract][Full Text] [Related]
42. Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids.
Liacouras CA; Wenner WJ; Brown K; Ruchelli E
J Pediatr Gastroenterol Nutr; 1998 Apr; 26(4):380-5. PubMed ID: 9552132
[TBL] [Abstract][Full Text] [Related]
43. Incidence of Childhood Eosinophilic Esophagitis in Central Brazil: How Many Are We Missing?
Gonçalves LO; Lopes MM; Rezende ER; Segundo GR
J Investig Allergol Clin Immunol; 2018; 28(4):241-245. PubMed ID: 29528033
[TBL] [Abstract][Full Text] [Related]
44. Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis.
Hamamoto N; Hashimoto T; Adachi K; Hirakawa K; Ishihara S; Inoue H; Taniura H; Niigaki M; Sato S; Kushiyama Y; Suetsugu H; Miyake T; Kinoshita Y
J Gastroenterol Hepatol; 2005 Feb; 20(2):281-6. PubMed ID: 15683433
[TBL] [Abstract][Full Text] [Related]
45. Transoral fundoplication offers durable symptom control for chronic GERD: 3-year report from the TEMPO randomized trial with a crossover arm.
Trad KS; Fox MA; Simoni G; Shughoury AB; Mavrelis PG; Raza M; Heise JA; Barnes WE
Surg Endosc; 2017 Jun; 31(6):2498-2508. PubMed ID: 27655380
[TBL] [Abstract][Full Text] [Related]
46. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
Habu Y; Oyasu K; Wakamatsu T; Sumitomo Y; Kiyota K; Inokuchi H; Kawai K
Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820
[TBL] [Abstract][Full Text] [Related]
47. Is fundoplication required after the Foker procedure for long gap esophageal atresia?
Wanaguru D; Langusch C; Krishnan U; Varjavandi V; Jiwane A; Adams S; Henry G
J Pediatr Surg; 2017 Jul; 52(7):1117-1120. PubMed ID: 28063681
[TBL] [Abstract][Full Text] [Related]
48. Histopathologic variability in children with eosinophilic esophagitis.
Shah A; Kagalwalla AF; Gonsalves N; Melin-Aldana H; Li BU; Hirano I
Am J Gastroenterol; 2009 Mar; 104(3):716-21. PubMed ID: 19209168
[TBL] [Abstract][Full Text] [Related]
49. [Comparison between histamine H2-blocker and proton pump inhibitor on the effects of initial treatment in reflux esophagitis].
Harasawa S
Nihon Rinsho; 2000 Sep; 58(9):1847-52. PubMed ID: 11004814
[TBL] [Abstract][Full Text] [Related]
50. Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis.
Iwakiri K
J Nippon Med Sch; 2017; 84(5):209-214. PubMed ID: 29142181
[TBL] [Abstract][Full Text] [Related]
51. Longitudinal Evaluation of Noninvasive Biomarkers for Eosinophilic Esophagitis.
Min SB; Nylund CM; Baker TP; Ally M; Reinhardt B; Chen YJ; Nazareno L; Moawad FJ
J Clin Gastroenterol; 2017 Feb; 51(2):127-135. PubMed ID: 27479142
[TBL] [Abstract][Full Text] [Related]
52. Results of short-and long-term medical treatment of gastroesophageal reflux disease (GERD).
Pohle T; Domschke W
Langenbecks Arch Surg; 2000 Aug; 385(5):317-23. PubMed ID: 11026702
[TBL] [Abstract][Full Text] [Related]
53. Management of gastroesophageal reflux disease.
Heidelbaugh JJ; Nostrant TT; Kim C; Van Harrison R
Am Fam Physician; 2003 Oct; 68(7):1311-8. PubMed ID: 14567485
[TBL] [Abstract][Full Text] [Related]
54. Management of Gastroesophageal Reflux Disease in Esophageal Atresia Patients: A Cross-Sectional Survey amongst International Clinicians.
van Lennep M; Gottrand F; Faure C; Omari TI; Benninga MA; van Wijk MP; Krishnan U
J Pediatr Gastroenterol Nutr; 2022 Aug; 75(2):145-150. PubMed ID: 35675703
[TBL] [Abstract][Full Text] [Related]
55. Characteristics of children and adolescents first prescribed proton pump inhibitors or histamine-2-receptor antagonists: an observational cohort study.
Ruigómez A; Kool-Houweling LMA; García Rodríguez LA; Penning-van Beest FJA; Herings RMC
Curr Med Res Opin; 2017 Dec; 33(12):2251-2259. PubMed ID: 28562108
[TBL] [Abstract][Full Text] [Related]
56. Risk Factors for Anastomotic Strictures after Esophageal Atresia Repair: Prophylactic Proton Pump Inhibitors Do Not Reduce the Incidence of Strictures.
Donoso F; Lilja HE
Eur J Pediatr Surg; 2017 Feb; 27(1):50-55. PubMed ID: 27769086
[No Abstract] [Full Text] [Related]
57. Esophagitis: a frequent consequence of gastroesophageal reflux in infancy.
Shub MD; Ulshen MH; Hargrove CB; Siegal GP; Groben PA; Askin FB
J Pediatr; 1985 Dec; 107(6):881-4. PubMed ID: 4067745
[TBL] [Abstract][Full Text] [Related]
58. Nonacid reflux in patients with chronic cough on acid-suppressive therapy.
Tutuian R; Mainie I; Agrawal A; Adams D; Castell DO
Chest; 2006 Aug; 130(2):386-91. PubMed ID: 16899836
[TBL] [Abstract][Full Text] [Related]
59. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Dohil R; Newbury R; Fox L; Bastian J; Aceves S
Gastroenterology; 2010 Aug; 139(2):418-29. PubMed ID: 20457157
[TBL] [Abstract][Full Text] [Related]
60. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
Tolia V; Gilger MA; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26121348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
